A Double‐Blind, Randomized, Placebo‐Controlled Trial of Ursodeoxycholic Acid (<scp>UDCA)</scp> in Parkinson's Disease

Abstract

High-dose UDCA is safe and well tolerated in early PD. Larger trials are needed to further evaluate the disease-modifying effect of UDCA in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.